Most Read Articles
Pearl Toh, 15 Jul 2019
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from the large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
15 Jul 2019
Fluticasone, swallowed from a multidose inhaler, and oral viscous budesonide slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis, a recent study has found.
2 days ago
Health-related quality of life (HRQoL) among patients with kidney stone is worse in those who are young and female than those who are older and male, according to a recent study. Non-Caucasian patients also have a lower HRQoL.
Tristan Manalac, 3 days ago
In patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI), admission Killip classification and creatinine and troponin levels are important cardiac mortality predictors, according to a recent Singapore study.

Tildrakizumab yields durable responses for psoriasis

Audrey Abella
19 Mar 2019

Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.

The reSURFACE 1 trial randomized 638 individuals (mean age 47.0 years, 67.6 percent male) to receive tildrakizumab 100 or 200 mg every 12 weeks. Of these, 506 (n=239 and 267 for 100 and 200 mg, respectively) entered the long-term extension phase (up to 192 weeks) upon achieving ≥50 percent improvement in Psoriasis Area and Severity Index score (PASI 50) at base study completion. The efficacy analysis was concluded at week 160 due to a drop in the number of participants. [AAD 2019, abstract 10508]

More than half of 100-mg recipients achieved PASI 75/90 at weeks 64 and 160 (87.8 percent/53.8 percent [week 64] and 84.4 percent/57.6 percent [week 160]). The rates were similar in the 200-mg arm (81.6 percent/52.4 percent [week 64] and 75.4 percent/50.8 percent [week 160]).

At week 160, 62.4 percent and 57.1 percent of patients receiving tildrakizumab 100 and 200 mg, respectively, achieved a Physician’s Global Assessment (PGA) response.

Fourteen percent of participants discontinued treatment at week 160, primarily due to patient withdrawal (5.7 percent), adverse events (AEs; 3.4 percent), and loss to follow-up (2.8 percent).

After almost 5 years of treatment, the cumulative number of patients with AEs of interest was low with both tildrakizumab dosages (<1.6 events/100 patient-years [PY]). Confirmed major adverse cardiovascular events (MACE) and drug-related hypersensitivity AEs occurred at very low rates (≤0.8 events/100 PY).

Similar results were observed in the extension phase of reSURFACE 2 (n=381 and 349 for tildrakizumab 100 and 200 mg, respectively), where a majority of participants achieved PASI 75/90 responses at week 52 (92.3 percent/69.9 percent [100 mg] and 88.7 percent/56.7 percent [200 mg]) and week 148 (89.1 percent/64.4 percent [100 mg] and 88.5 percent/61.7 percent [200 mg]). [AAD 2019, abstract 10510]

At week 148, PGA response was achieved by two-thirds of participants receiving tildrakizumab 100 and 200 mg (65.1 percent and 66.4 percent, respectively).

There was a 15.5-percent discontinuation rate by week 148 primarily due to treatment withdrawal (6.0 percent) followed by AEs (2.3 percent).

AE incidence rates in reSURFACE 2 were similar to reSURFACE 1, with low cumulative numbers of patients with AEs of interest for both 100/200-mg dosages (1.2/1.3 PY for severe infections, 0.3/0.6 for confirmed extended MACE, and 0.3/0.2 for drug-related hypersensitivity reactions).

Taken together, with over 3 years of extension, the PASI and PGA response rates were considered high and durable, noted the researchers. The low AE rates suggest a lack of dose effect on safety events, they added.

 

Editor's Recommendations
Most Read Articles
Pearl Toh, 15 Jul 2019
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from the large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
15 Jul 2019
Fluticasone, swallowed from a multidose inhaler, and oral viscous budesonide slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis, a recent study has found.
2 days ago
Health-related quality of life (HRQoL) among patients with kidney stone is worse in those who are young and female than those who are older and male, according to a recent study. Non-Caucasian patients also have a lower HRQoL.
Tristan Manalac, 3 days ago
In patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI), admission Killip classification and creatinine and troponin levels are important cardiac mortality predictors, according to a recent Singapore study.